Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed malignancy

  * Metastatic or unresectable disease
  * Standard curative or palliative measures do not exist or are no longer effective
* Measurable or non-measurable disease

  * Measurable disease is defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
  * Non-measurable disease is defined as all other lesions (including small lesions and truly non-measurable lesions), including any of the following:

    * Bone lesions
    * Ascites
    * Pleural/pericardial effusion
    * Lymphangitis cutis/pulmonis
    * Abdominal masses that are not confirmed and followed by imaging techniques
    * Cystic lesions
* No brain metastasis
* Healthy blood donor available meeting the following criteria:

  * Willing to be included in the White Cell Donor Registry created for this study
  * Willing to undergo granulocyte apheresis at the American Red Cross
  * ABO compatible with the patient
  * HLA-mismatched with the patient
  * Demonstrates ≥ 60% cytotoxic killing activity (CKA) as determined by in vitro white cell kill assay

    * Less than 60% CKA allowed if deemed suitable by the investigators

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 4 months
* ANC ≥ 1,000/µL
* Platelet count \> 100,000/µL (platelet transfusion independent)
* Serum bilirubin ≤ 2 mg/dL
* AST and ALT \< 3 times upper limit of normal
* Serum creatinine ≤ 2 mg/dL
* No uncontrolled diabetes mellitus
* No myocardial infarction within the past 30 days
* No active serious infection
* No HIV infection
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Negative panel reactive antibody test (i.e., absence of serum HLA antibody)

PRIOR CONCURRENT THERAPY:

* No prior fludarabine phosphate
* No prior stem cell transplantation
* At least 4 weeks since prior medical therapy, radiotherapy, or surgery
* More than 30 days since prior immunosuppressive agents other than steroids